TBPH
Theravance Biopharma Inc
NASDAQ: TBPH · HEALTHCARE · BIOTECHNOLOGY
$16.52
-2.88% today
Updated 2026-05-11
Market cap
$876.78M
P/E ratio
7.63
P/S ratio
7.99x
EPS (TTM)
$2.23
Dividend yield
—
52W range
$8 – $21
Volume
0.6M
Theravance Biopharma Inc (TBPH) Financial statements
SEC filings — annual and quarterly data.
Profit margin
104.30%
Operating margin
-33.10%
ROE
50.20%
ROA
0.76%
Debt/equity
0.19x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2011 | $14.85M | $-109.33M | 74.12% | -736.06% | -736.06% |
| 2012 | $130.15M | $-9.57M | 12.41% | -7.36% | -7.36% |
| 2013 | $226000.00 | $-156.28M | -53,253.54% | -69,152.21% | -69,152.21% |
| 2014 | $11.69M | $-237.04M | 65.28% | -1,989.55% | -2,028.05% |
| 2015 | $42.13M | $-182.22M | 88.95% | -431.80% | -432.56% |
| 2016 | $48.65M | $-190.67M | 94.05% | -370.96% | -391.94% |
| 2017 | $15.39M | $-285.40M | 60.81% | -1,690.65% | -1,854.97% |
| 2018 | $60.37M | $-215.52M | 98.82% | -395.48% | -357.01% |
| 2019 | $73.41M | $-236.46M | 100.00% | -343.14% | -322.08% |
| 2020 | $71.86M | $-278.02M | 100.00% | -414.19% | -386.90% |
| 2021 | $55.31M | $-199.43M | -250.12% | -466.06% | -360.55% |
| 2022 | $51.35M | $872.13M | -23.46% | -179.09% | 1,698.54% |
| 2023 | $57.42M | $-55.19M | 29.26% | -97.58% | -96.11% |
| 2024 | $64.38M | $-56.42M | 100.00% | -72.92% | -87.63% |
| 2025 | $107.46M | $105.89M | 94.87% | -12.33% | 98.54% |